PlainRecalls
FDA Drug Moderate Class II Terminated

Nizatidine Capsules, USP 300 mg, Rx Only, Mylan Pharmaceuticals Inc., NDC 0378-5300-93.

Reported: January 29, 2020 Initiated: January 7, 2020 #D-0792-2020

Product Description

Nizatidine Capsules, USP 300 mg, Rx Only, Mylan Pharmaceuticals Inc., NDC 0378-5300-93.

Reason for Recall

CGMP Deviations: Trace amounts of an impurity, N-nitrosodimethylamine (NDMA) was detected in the API Nizatidine.

Details

Units Affected
16,944 bottles of 30 capsules
Distribution
Product was distributed to wholesalers, distributors , retail pharmacies, charitable organizations and mail order pharmacies throughout the United States and the product may have been further distributed.
Location
Morgantown, WV

Frequently Asked Questions

What product was recalled?
Nizatidine Capsules, USP 300 mg, Rx Only, Mylan Pharmaceuticals Inc., NDC 0378-5300-93.. Recalled by Mylan Pharmaceuticals Inc.. Units affected: 16,944 bottles of 30 capsules.
Why was this product recalled?
CGMP Deviations: Trace amounts of an impurity, N-nitrosodimethylamine (NDMA) was detected in the API Nizatidine.
Which agency issued this recall?
This recall was issued by the FDA Drug on January 29, 2020. Severity: Moderate. Recall number: D-0792-2020.